Genmab (GMAB) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Genmab’s revenue surged by 29% in the first nine months of 2024, reaching DKK 15,085 million, primarily driven by increased royalties from its collaborations and strong sales of its cancer treatments. The company received conditional marketing authorization in Europe for TEPKINLY®, expanding its portfolio and signaling growth potential. Genmab’s updated financial guidance reflects a robust performance, though it remains focused on disciplined investment strategies.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
